The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
RNS could drop any time regarding StemPrinter and you could loose out. If your not in you will loose out of a share one for one.
People might take some profit and hope to come back in but its a close call as the news is soon to be announced.
Interesting interview and great potential within the cruise industry as they are hemorrhaging money with the ships stuck in harbours.
4 seconds to test that's a game changer as opposed to 48 -72:hours.
6-8 weeks nice RNS and some great news. Pencil that in your diary.
Interesting presentation with CF always great at delivering and a good enough reason why I am in this company for the long run.
Picked up on the PrEPBiopharm Inc (USA), 62.6% owned by Open Orphan
• has a viral prophylactic with expected utility against Covid-19
On the slide. Another spin off and back to the share holders. We have a number of spin offs and cash or shares back.
Any good reason why to be in and opportunity to top up.
Never invest in the copper company. How not to present your company . Abysmal.
My research show that OO has great fundamentals and CF at the helm with his great past track record also he is in with his own cash. Contracts and cash is king. Say no more.
I think Arcadia have spent there load and only have a small holding. They might be well mear there exited already as they do not need to report any thing below 5% . I have only seen one 12k which is there figure of sells. Great opportunity to top up .
As I stated CF has prevously commented on the contract value of lab hire in interviews. The figures are known and what the potential value of upto 12 contracts to be signed .
Great news with more contracts to follow. If anyone follows this share they will know from previous interviews with CF the value of these contracts ." Possible 12 contracts over 6 to 12 months which Is filling the lab time. "
The RNs lists the name parties who are using the lab which shows the commercial interest not just for Coronavirus.
The lab costs are all cash into the bottom line.
RNS is out. It was a bit delayed but good news.
They started to off loaded no core business starting last year and non profit business. Good indicators for slimming down and making the balance sheet against pipeline look good for potential biddings. With the back ground of new main and Archie departure. The opportunity looks good just my option from past knowledge.
The sp is a bargain. Company looks good as a buy out and with his back ground at Cobham has a good knowledge of take overs. Would it be a good thing for share holders ? Short term probably as cash and shares would come our way. SP quoted at 6.50 forecasts so buyers will be on the prowl to scope Bab**** up. We could see large share buys and positioning going on. I am long term holder and had some nice dividends. I see these will be returned in the near future. Nice pipe line business. Great opportunity to top up .
Asked "will you be selling this commercially or just to the NHS . Colin "this is a government initiative!
No massive production numbers or commercial sales is a negative . So no great monetary sales.
Jobeth and Haylock . One and the same person. Does not take rocket science to work it out.
Using a heading like Boatman says it all.
Market cap and what they have in the pipeline makes this cheap sp below £3.20. Long time holder and with the volatility of 10% can easily be made on these shares. I see this going only one way once Archie goes and recently disposed of the helicopter cash loosing asset. Top up time.
Success and delivered.
https://www.bab****international.com/news/from-zero-to-zephyr-plus-bab****-ventilator-team-update/
24th June . 60,000 sq feet facility. This gives us an increase in capacity to draw upon when the future requires. Excellent release today.
Today we celebrate the completion of an extensive renovation project on our Fast Trak cGMP contract biomanufacturing and process development site in Marlborough, Massachusetts, USA. The upgraded facility offers increased capacity and cutting-edge automation technologies that improve efficiencies to bring novel therapeutics to market faster
Large number of buys and delay trades showing at end of the day which looks good. Some nice news in the last few days which pushed us up and some profit taking. Looks fairly solid at £1 with a wide 10% spread ? Topping up at 98p seems a good move before we get the next good news in the next two weeks. Dipping out could loss you the StemPrintER value.
Swapleber. You must of watched another program. Have watched the interview from start to finish. Interesting interview. The government's under pressure to relax the 14 day quarantine for flights so a test prior to flights might be an option.